Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fragile X syndrome
Biotech
Harmony halts genetic disease program after phase 3 failure
After its cannabidiol gel failed a phase 3 trial in fragile X syndrome, Harmony has paused development of the asset in a different genetic disease.
Darren Incorvaia
Nov 4, 2025 12:45pm
Harmony's pivotal trial flops as placebo response causes discord
Sep 24, 2025 9:35am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
Stalicla pledges $270M for Novartis' failed fragile X asset
Jan 9, 2023 8:06am
Merck KGaA taps into Quris' stem cell-powered drug screening AI
Feb 14, 2022 10:15am
Ovid pens deal to offload twice-failed former lead program
Feb 8, 2022 9:10am
